Wempacli 100mg Injection contains Paclitaxel at a concentration of 6 mg/ml and is indicated for the treatment of various malignancies including ovarian, breast, and non-small cell lung cancers. Paclitaxel is a cytotoxic agent that stabilizes microtubules and inhibits their depolymerization, thereby disrupting normal mitotic spindle function and arresting cell division in the G2/M phase of the cell cycle. This mechanism leads to apoptosis of rapidly dividing cancer cells. Wempacli is administered intravenously under strict medical supervision, with dosing regimens tailored according to the specific cancer type, patient response, and tolerability. Premedication with corticosteroids, antihistamines, and H2 antagonists is recommended to reduce the risk of hypersensitivity reactions commonly associated with Paclitaxel. Adverse effects may include neutropenia, peripheral neuropathy, alopecia, myalgia, and hypersensitivity reactions. Close monitoring of blood counts and organ function is essential during therapy. Wempacli should be used with caution in patients with pre-existing neuropathy or hepatic impairment. This product is intended for use by healthcare professionals experienced in chemotherapy administration. Proper handling and disposal procedures must be followed to avoid exposure risks. Wempacli 100mg Injection offers an effective chemotherapeutic option within combination or single-agent protocols for the management of advanced solid tumors.